Yes, and to me too results are first , and the most important. Everything else will be few months sooner or later , but will be , if patients are doing very well. I know final , the most important things for FDA are results from treatment and side effects of medicine , and here we see very good results and NO serious side effects.
yah but everything just got stretched much later. Isn't there a 100 patient placebo arm being added to the phase 3 monotherapy? So that is expected to start Q4 2016 and probably won't have results until Q1 2018 or later. The adjunct therapy may finish with results in 2017 though, but the filing will take many months as well. All in all too many delays good to hold a core position here for long term though.
But it would be more prudent to hold small core position now and then wait to buy more shares later when it drops.
News 
Market Data 
Discover 
AI
